Disclosure and sourcing

PRP Direct is an Emcyte distributor. We have a commercial interest in the systems on this page. That is exactly why every specification here is quoted from the manufacturer's own published documentation and named at the point of use, so you can check it against the source rather than take our word for it.

Where a manufacturer does not publish a figure, we say so instead of estimating. We have not independently tested any device referenced here, and no figure on this page is our own measurement.

System selection guide

Choosing a PRP system for orthopedics and sports medicine

Choose an orthopedic PRP system on four specifications: platelet concentration, whether the leukocyte profile is selectable, the final output volume, and whether one centrifuge also runs bone marrow. The published literature does not settle leukocyte-rich versus leukocyte-poor for joints, so a system that lets the physician select either keeps that decision at the chair.

Educational content on device specifications, not clinical advice. Cited studies are general PRP-class literature, not outcome data for any product distributed by PRP Direct.

What should you actually compare?

Compare four things, and insist on a number for each. Marketing copy across this category is close to interchangeable, so the only useful comparison is the specification sheet.

Platelet concentration, stated as a multiple of the patient's own baseline or as platelet recovery percentage.
Leukocyte profile, and specifically whether it is fixed by the device or selected by the physician.
Final output volume, because a concentration figure alone does not tell you the delivered dose.
Platform coverage, meaning whether the same centrifuge runs bone marrow and adipose systems or whether adding those means buying another machine.

Two things belong on that list that most buyers skip. The bench workflow: how many disposables the preparation touches and how many times the centrifuge is counterbalanced. And the working window: Emcyte's instructions direct that prepared plasma be used within 4 hours of the draw, per current AABB guidelines, which is what makes point-of-care preparation a same-visit workflow.

Is leukocyte-rich or leukocyte-poor PRP better for joints?

The published literature has not settled it, and the major sources disagree. This section reports what those sources say. It is general background on the PRP class, not a claim about any product sold on this site, and not a recommendation for any protocol.

Source	Type and size	What it reports on LR vs LP
Riboh et al., AJSM 2016;44(3):792-800	Network meta-analysis, 9 studies, 1,055 patients	Leukocyte-poor PRP produced better WOMAC scores than hyaluronic acid and placebo; leukocyte-rich did not show that difference. Adverse-reaction rates similar.
Abbas et al., JBJS Am 2022;104(6):559-570	Network meta-analysis, 23 studies, 2,260 patients	No significant difference in outcome measures or local adverse reactions between LP-PRP and LR-PRP; leukocyte concentration does not play a significant role in patient-reported outcomes for knee OA.
AAOS Knee OA guideline, 3rd ed., 2021	Clinical practice guideline	Determining the better choice between LR-PRP and LP-PRP is still inconclusive, but at this time appears to favor LR-PRP. PRP recommendation carries a Limited strength of recommendation.
Romandini et al., AJSM 2024;52(13):3212-3222	Double-blind RCT, 12-month follow-up	Leukocytes did not affect the safety or efficacy of intra-articular PRP for knee OA; LR and LP comparable at all follow-up points, no difference in adverse events.
Fitzpatrick et al., AJSM 2017;45(1):226-233	Meta-analysis of RCTs, tendinopathy	Good evidence to support a single injection of LR-PRP under ultrasound guidance in tendinopathy. Soft-tissue setting, not intra-articular.

General literature on the PRP class, cited as background. Not outcome data for any product distributed by PRP Direct, and nothing here recommends a leukocyte protocol or claims any preparation treats any condition. The AAOS statement reads: "Platelet-rich plasma (PRP) may reduce pain and improve function in patients with symptomatic osteoarthritis of the knee," at a Limited strength of recommendation.

Why does a selectable leukocyte profile matter?

Because an unsettled question should not be answered by your equipment. A device with a fixed leukocyte profile has already made the call for every case you will run on it. A device that lets the physician select a neutrophil-rich or neutrophil-poor preparation leaves the call where it belongs, and lets a practice change its protocol without changing its capital equipment. That is an operational argument, not a clinical one, and it matters most in a mixed book: intra-articular work on large joints alongside tendon and soft-tissue cases.

Emcyte reports that PurePRP SP produces either a neutrophil-rich or neutrophil-poor preparation from the same device, with the leukocyte fraction isolated inside the concentrating system so it can be retained or removed. That is a manufacturer-reported device capability. It describes what the device can produce, not how any preparation performs in a patient.

How much volume do larger joints need?

Kit size sets the ceiling on final volume, so the kit is chosen before the case. Delivered dose in the literature is reported as an absolute platelet count in a stated volume, not concentration alone; one randomized knee study specified 10 billion platelets in 8 mL. Concentration multiplied by output volume produces that number, which is why both belong on a spec comparison.

Kit	Whole blood drawn	Sodium citrate	Final PRP volume	SKU
PurePRP SP 30 mL	27 mL	3 mL	3 mL	GS30-SP
PurePRP SP 60 mL	54 mL	6 mL	7 mL	GS60-SP
PurePRP SP 120 mL	54 mL per device, two devices	6 mL per device	7 mL per device	GS120-SP

Manufacturer-reported, from the Emcyte PurePRP SupraPhysiologic Concentrating System instructions for use. These are the volumes in the written protocol; Emcyte states the physician controls the final treatment volume. Volumes describe device output, not a dose recommendation or efficacy claim.

Practically, three things push toward larger kits: large joints, multiple sites in one visit, and bilateral treatment. The 30 mL kit finishes at a volume suited to a single focal target; the 60 mL kit is the common orthopedic configuration; the 120 mL configuration runs two concentrating devices in one session.

Which system fits which workflow?

Every system below runs on the Sapphire centrifuge, so the platform decision is made once. Specifications are manufacturer-reported.

System	Category	Disposable and workflow	Manufacturer-reported output
PurePRP SP	PRP	One integrated disposable, counterbalanced once, double spin	≥90% platelet yield, ≥6x baseline, <1% hematocrit, 7 mL; neutrophil-rich or -poor selectable
Pure Two PRP	PRP	Two disposables, counterbalanced twice, double spin	Platelet counts comparable to PurePRP SP
AbsolutePRP (Pure Gold)	PRP	Single-spin disposable, one fast spin	Lower concentration than SP; entry configuration
PureBMC SP	Bone marrow concentrate	One integrated concentrating device, counterbalanced once, double spin	≥80% total nucleated cell yield, ≥80% HSCs, ≥80% platelet yield, ≥6x baseline, <20% hematocrit, 7 mL
Pure Two BMC	Bone marrow concentrate	Cell separator plus cell concentrator, counterbalanced twice	Cell recovery comparable to PureBMC SP
Sapphire	Centrifuge	One machine runs the PRP, bone marrow, and adipose systems	Platform for the systems above

Manufacturer-reported device specifications and workflow differences. Output figures describe what the device produces in the syringe, not the clinical performance of any prepared biologic. The platelet-to-plastic contact argument for the single-disposable design is a handling rationale, not an outcome claim.

Where does bone marrow concentrate fit?

Bone marrow concentrate is the second platform most orthopedic practices add, and on this line it does not require a second centrifuge. PureBMC SP is the bone marrow counterpart to PurePRP SP: one integrated concentrating device, one counterbalance, physician control over the final volume. Pure Two BMC is the two-device version, with comparable cell recovery. Emcyte reports PureBMC SP figures of at least 80% total nucleated cell yield, at least 80% hematopoietic stem cells, at least 80% platelet yield, at least 6x baseline, a hematocrit under 20%, and a 7 mL BMC volume, prepared in under 10 minutes. Those are device output specifications.

Price a system for the cases you run

Tell us the joints you treat, the volumes you run, and whether you want bone marrow on the same platform. We reply with real numbers within one business day.

Request a quote

PRP Direct distributes 510(k)-cleared autologous blood-processing devices. Manufacturer specifications describe how the device processes blood and are not claims of clinical efficacy of the prepared biologic. This guide explains device specifications and system selection; it does not diagnose, recommend a protocol, or claim a clinical outcome. Treatment decisions belong to a licensed clinician.

What these devices are cleared for

Emcyte's instructions for use define the labeled indication for the PurePRP Supraphysiologic Concentrating System as follows, quoted verbatim:

"The PurePRP^® Supraphysiologic Concentrating System is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of blood at the patient's point of care. The PRP is mixed with autograft and allograft bone prior to application to an orthopedic site to improve bone graft handling characteristics."

The same document states: "The PRP prepared by this device has not been evaluated for any clinical indications." It also states that the safety and effectiveness of the device for in vivo indications such as bone healing and hemostasis have not been established, and that the PRP prepared by the device is not indicated for delivery to the patient's circulatory system.

Any application other than the labeled indication falls outside it. That is not unusual in this field, and it is not something PRP Direct can authorize, recommend, or direct. It rests on the independent clinical judgment of a licensed physician, exercised under their own license and their own informed-consent process. We sell equipment and publish what the manufacturer publishes about it. We do not advise on clinical application.

PRP Direct is a distributor of Emcyte point-of-care blood-processing devices. Emcyte states these systems are 510(k)-cleared as blood-processing devices; clearance covers how a device processes blood, it is not a clearance of the prepared PRP to treat any condition, and no PRP therapy is FDA-approved for a specific indication. Manufacturer specifications are reproduced as the manufacturer's statements, have not been independently verified by PRP Direct, and are not claims of clinical efficacy. Manufacturers revise specifications without notice, and the instructions for use packaged with your kit supersede anything published here. Nothing on this page is dosing, protocol, clinical, or medical advice, and nothing here should be relied upon in making a clinical decision. Product names and trademarks belong to their respective owners.